X Coded, linked data in BTRIS (automatic for activities in the Clinical Center) X Identified or coded, linked data with approved outside collaborators under appropriate agreements How and where will the data be shared? Data will be shared through: X An NIH-funded or approved public repository: www.clinicaltrials.gov X BTRIS (automatic for activities in the Clinical Center) X Approved outside collaborators under appropriate individual agreements X Publication and/or public presentations When will the data be shared? X Before publication X At the time of publication or shortly thereafter 5.3 RESPONSE C RITERIA 5.3.1 Antitumor effect – Solid Tumors Restaging bone scans and CT scan of chest, abdomen and pelvis will be obtained every 12 weeks (refer to Study Calendar in section 3.4). For patients who have stable disease beyond 2 years and a PSA less than 1.0 ng/ml, they can defer restaging scans based on investigator discretion. Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [40]. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. For exploratory purpose, changes in PSA and measurable lesions will be analyzed for efficacy according to the PCWG2 recommendations[23] . The recommended PSA progressions criteria will not be applied to the study as the criteria are arbitrarily proposed and do not necessarily reflect overall disease status. PSA values will be captured at each visit and PSA declines and progression will be followed. PSA is not sufficient in the evaluation of disease progression in this patient population. This is consistent with the recent recommendations by the Prostate Cancer Clinical Trials Working Group 2 [23]. Progression will be determined by radiographic evidence as discussed below or by clinical symptoms (symptomatic clinical progression). 42 Short Title: Enzalutamide Vaccine in mCRPC Version Date: 03/29/2022 5.3.2 Definitions Evaluable for toxicity: All patients will be evaluable for toxicity from the time of their first treatment with enzalutamide with or without PSA-TRICOM. Evaluable for objective response: All of the patients who met the eligibility criteria (with the possible exception of those who received no study medication) are evaluable for response.